Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register

Detalhes bibliográficos
Autor(a) principal: Mazya, M
Data de Publicação: 2014
Outros Autores: Ahmed, N, Ford, G, Hobohm, C, Mikulik, R, Paiva Nunes, A, Wahlgren, N
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/3874
Resumo: Background and purpose: Intracerebral hemorrhage after treatment with intravenous recombinant tissue-type plasminogen activator for ischemic stroke can occur in local relation to the infarct, as well as in brain areas remote from infarcted tissue. We aimed to describe risk factors, 3-month mortality, and functional outcome in patients with the poorly understood complication of remote intracerebral hemorrhage, as well as local intracerebral hemorrhage. Methods: In this study, 43 494 patients treated with intravenous recombinant tissue-type plasminogen activator, with complete imaging data, were enrolled in the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) during 2002 to 2011. Baseline data were compared among 970 patients (2.2%) with remote parenchymal hemorrhage (PHr), 2325 (5.3%) with PH, 438 (1.0%) with both PH and PHr, and 39 761 (91.4%) without PH or PHr. Independent risk factors for all hemorrhage types were obtained by multivariate logistic regression. Results: Previous stroke (P=0.023) and higher age (P<0.001) were independently associated with PHr, but not with PH. Atrial fibrillation, computed tomographic hyperdense cerebral artery sign, and elevated blood glucose were associated with PH, but not with PHr. Female sex had a stronger association with PHr than with PH. Functional independence at 3 months was more common in PHr than in PH (34% versus 24%; P<0.001), whereas 3-month mortality was lower (34% versus 39%; P<0.001). Conclusions: Differences between risk factor profiles indicate an influence of previous vascular pathology in PHr and acute large-vessel occlusion in PH. Additional research is needed on the effect of pre-existing cerebrovascular disease on complications of recanalization therapy in acute ischemic stroke.
id RCAP_eb89d3c682279ce5e0af24028cdf2355
oai_identifier_str oai:repositorio.chlc.pt:10400.17/3874
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis RegisterHSJ NEUAge FactorsAgedBrain Ischemia* / chemically inducedBrain Ischemia* / diagnostic imagingBrain Ischemia* / mortalityCerebral Hemorrhage* / chemically inducedFemaleMaleCerebral Hemorrhage* / diagnostic imagingHumansCerebral Hemorrhage* / mortalityFibrinolytic Agents / adverse effects*Fibrinolytic Agents / therapeutic useMiddle AgedRadiographyRecombinant Proteins / adverse effectsRecombinant Proteins / therapeutic useRetrospective StudiesStroke* / diagnostic imagingStroke* / drug therapyThrombolytic Therapy / adverse effects*Tissue Plasminogen Activator / adverse effects*Tissue Plasminogen Activator / therapeutic useBackground and purpose: Intracerebral hemorrhage after treatment with intravenous recombinant tissue-type plasminogen activator for ischemic stroke can occur in local relation to the infarct, as well as in brain areas remote from infarcted tissue. We aimed to describe risk factors, 3-month mortality, and functional outcome in patients with the poorly understood complication of remote intracerebral hemorrhage, as well as local intracerebral hemorrhage. Methods: In this study, 43 494 patients treated with intravenous recombinant tissue-type plasminogen activator, with complete imaging data, were enrolled in the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) during 2002 to 2011. Baseline data were compared among 970 patients (2.2%) with remote parenchymal hemorrhage (PHr), 2325 (5.3%) with PH, 438 (1.0%) with both PH and PHr, and 39 761 (91.4%) without PH or PHr. Independent risk factors for all hemorrhage types were obtained by multivariate logistic regression. Results: Previous stroke (P=0.023) and higher age (P<0.001) were independently associated with PHr, but not with PH. Atrial fibrillation, computed tomographic hyperdense cerebral artery sign, and elevated blood glucose were associated with PH, but not with PHr. Female sex had a stronger association with PHr than with PH. Functional independence at 3 months was more common in PHr than in PH (34% versus 24%; P<0.001), whereas 3-month mortality was lower (34% versus 39%; P<0.001). Conclusions: Differences between risk factor profiles indicate an influence of previous vascular pathology in PHr and acute large-vessel occlusion in PH. Additional research is needed on the effect of pre-existing cerebrovascular disease on complications of recanalization therapy in acute ischemic stroke.American Heart AssociationRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEMazya, MAhmed, NFord, GHobohm, CMikulik, RPaiva Nunes, AWahlgren, N2021-10-12T14:54:53Z20142014-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/3874engStroke. 2014 Jun;45(6):1657-63.10.1161/STROKEAHA.114.004923.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-10-28T10:29:49Zoai:repositorio.chlc.pt:10400.17/3874Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-10-28T10:29:49Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
title Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
spellingShingle Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
Mazya, M
HSJ NEU
Age Factors
Aged
Brain Ischemia* / chemically induced
Brain Ischemia* / diagnostic imaging
Brain Ischemia* / mortality
Cerebral Hemorrhage* / chemically induced
Female
Male
Cerebral Hemorrhage* / diagnostic imaging
Humans
Cerebral Hemorrhage* / mortality
Fibrinolytic Agents / adverse effects*
Fibrinolytic Agents / therapeutic use
Middle Aged
Radiography
Recombinant Proteins / adverse effects
Recombinant Proteins / therapeutic use
Retrospective Studies
Stroke* / diagnostic imaging
Stroke* / drug therapy
Thrombolytic Therapy / adverse effects*
Tissue Plasminogen Activator / adverse effects*
Tissue Plasminogen Activator / therapeutic use
title_short Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
title_full Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
title_fullStr Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
title_full_unstemmed Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
title_sort Remote or Extraischemic Intracerebral Hemorrhage--an Uncommon Complication of Stroke Thrombolysis: Results from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register
author Mazya, M
author_facet Mazya, M
Ahmed, N
Ford, G
Hobohm, C
Mikulik, R
Paiva Nunes, A
Wahlgren, N
author_role author
author2 Ahmed, N
Ford, G
Hobohm, C
Mikulik, R
Paiva Nunes, A
Wahlgren, N
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Mazya, M
Ahmed, N
Ford, G
Hobohm, C
Mikulik, R
Paiva Nunes, A
Wahlgren, N
dc.subject.por.fl_str_mv HSJ NEU
Age Factors
Aged
Brain Ischemia* / chemically induced
Brain Ischemia* / diagnostic imaging
Brain Ischemia* / mortality
Cerebral Hemorrhage* / chemically induced
Female
Male
Cerebral Hemorrhage* / diagnostic imaging
Humans
Cerebral Hemorrhage* / mortality
Fibrinolytic Agents / adverse effects*
Fibrinolytic Agents / therapeutic use
Middle Aged
Radiography
Recombinant Proteins / adverse effects
Recombinant Proteins / therapeutic use
Retrospective Studies
Stroke* / diagnostic imaging
Stroke* / drug therapy
Thrombolytic Therapy / adverse effects*
Tissue Plasminogen Activator / adverse effects*
Tissue Plasminogen Activator / therapeutic use
topic HSJ NEU
Age Factors
Aged
Brain Ischemia* / chemically induced
Brain Ischemia* / diagnostic imaging
Brain Ischemia* / mortality
Cerebral Hemorrhage* / chemically induced
Female
Male
Cerebral Hemorrhage* / diagnostic imaging
Humans
Cerebral Hemorrhage* / mortality
Fibrinolytic Agents / adverse effects*
Fibrinolytic Agents / therapeutic use
Middle Aged
Radiography
Recombinant Proteins / adverse effects
Recombinant Proteins / therapeutic use
Retrospective Studies
Stroke* / diagnostic imaging
Stroke* / drug therapy
Thrombolytic Therapy / adverse effects*
Tissue Plasminogen Activator / adverse effects*
Tissue Plasminogen Activator / therapeutic use
description Background and purpose: Intracerebral hemorrhage after treatment with intravenous recombinant tissue-type plasminogen activator for ischemic stroke can occur in local relation to the infarct, as well as in brain areas remote from infarcted tissue. We aimed to describe risk factors, 3-month mortality, and functional outcome in patients with the poorly understood complication of remote intracerebral hemorrhage, as well as local intracerebral hemorrhage. Methods: In this study, 43 494 patients treated with intravenous recombinant tissue-type plasminogen activator, with complete imaging data, were enrolled in the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) during 2002 to 2011. Baseline data were compared among 970 patients (2.2%) with remote parenchymal hemorrhage (PHr), 2325 (5.3%) with PH, 438 (1.0%) with both PH and PHr, and 39 761 (91.4%) without PH or PHr. Independent risk factors for all hemorrhage types were obtained by multivariate logistic regression. Results: Previous stroke (P=0.023) and higher age (P<0.001) were independently associated with PHr, but not with PH. Atrial fibrillation, computed tomographic hyperdense cerebral artery sign, and elevated blood glucose were associated with PH, but not with PHr. Female sex had a stronger association with PHr than with PH. Functional independence at 3 months was more common in PHr than in PH (34% versus 24%; P<0.001), whereas 3-month mortality was lower (34% versus 39%; P<0.001). Conclusions: Differences between risk factor profiles indicate an influence of previous vascular pathology in PHr and acute large-vessel occlusion in PH. Additional research is needed on the effect of pre-existing cerebrovascular disease on complications of recanalization therapy in acute ischemic stroke.
publishDate 2014
dc.date.none.fl_str_mv 2014
2014-01-01T00:00:00Z
2021-10-12T14:54:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/3874
url http://hdl.handle.net/10400.17/3874
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Stroke. 2014 Jun;45(6):1657-63.
10.1161/STROKEAHA.114.004923.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Heart Association
publisher.none.fl_str_mv American Heart Association
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817548655170682880